Gov’t to cut prices for 2,600 prescription medicines starting January

According to the report, domestic enterprises have produced pharmaceutical products worth 5 trillion UZS this year, exported goods valued at $172 million, and attracted $286 million in investments – including $257 million in foreign direct investment. To strengthen quality control, international standards have been widely introduced: Good Manufacturing Practice (GMP) at 61 enterprises, Good Distribution Practice (GDP) at 486 warehouses, and Good Pharmacy Practice (GPP) at 9,450 pharmacies across the country.

The presentation also addressed the issue of price manipulation in the reference pricing system for imported medicines. Of the 7,600 imported medicines currently registered, 4,900 are not listed in the reference price registries of relevant countries.

To address this, the government plans to cut prices for 2,600 types of prescription medicines by an average of 40–50 percent starting from January 1, 2026.

The president also reviewed measures to enhance transparency and efficiency in public procurement of pharmaceutical products. To eliminate low-quality purchases and reduce corruption risks in healthcare institutions, all state procurements will be conducted through a dedicated electronic platform – farma.xarid.uz.

Only suppliers and manufacturers holding valid certificates for production, delivery, and product safety will be allowed to participate. Information on procurement volumes, as well as registries of certified manufacturers and distributors, will be made publicly available. The system will automatically ensure that purchase prices do not exceed established reference prices.

President Mirziyoyev instructed that by January 1, 2026, a specialized digital platform be developed within this system to manage the procurement needs and inventory of medicines and medical equipment in public healthcare facilities.

He was also presented with a new procedure for state registration of medicines and medical devices, designed to expand access to safe, effective, and high-quality pharmaceuticals. The procedure envisions establishing domestic medicine production through technology transfer, enabling foreign pharmaceutical companies to manufacture their products locally and register them through an accelerated process.

A framework will also be created for the introduction of innovative biomedicine products used in tissue regeneration, organ restoration, and functional recovery. Clinical trials and assessments of generic medicines will be conducted in line with international standards, while their registration timelines will be shortened.

Medical devices classified under safety category 1 will be exempt from laboratory testing and clinical trials, except for sterile, measuring, and invasive products.

Approving the proposals, President Mirziyoyev instructed that by the end of 2025, 32 investment projects worth $166 million be fully implemented. These projects are expected to create 1,500 new jobs, expand production and exports, and contribute to lowering prescription drug prices.